# Grand Mount Capital

> Grand Mount Capital is a VC fund backing Biotechnology, Medical and Health Care. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: Jul 2026
- Lead investor: 13%
- Last updated: Aug 2026
- Website: https://grandmountaincapital.com/

Grand Mount Capital is a VC fund focused on Biotechnology and Medical. Grand Mountain Capital or to discuss a specific investment opportunity.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Medical | 3 | 38% |
| Health Care | 3 | 38% |
| Medical Device | 2 | 25% |
| Pharmaceutical | 2 | 25% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 38% |
| Series A | 2 | 25% |
| Angel | 1 | 13% |
| Series C | 1 | 13% |
| Series D | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 7 | 88% |
| France | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AIsphere | AIsphere focuses on visual multimodal large models and empowering content producers in many sectors and scenarios with AIGC technology. | $139M | Series C | Jul 14, 2026 |  |
| Qinghan Medical | Qinghan Medical is a medical equipment research and development manufacturer |  | Angel | Jan 19, 2023 |  |
| Spectrum Medical | Spectrum Medical is a clinical mass spectrometry product platform in the field of medical clinical testing | $33.6M | Series A | Jun 23, 2022 |  |
| Zhenzhun Biotech | It is a bio-tech enterprise integrating R&D, production and sales of in vitro diagnostic equipment consumables. Life and health business. The core team includes both enterprise management experts from leading medical device companies in the world, as well as scientists and technical experts in micro-nano processing, precision instruments, imagealgorithms, and biological reagents. We have successfully developed China's first chip-type digital PCR instrument with independent intellectual property rights. 臻Quan Biotechnology is in the stage of rapid development, and we invite talented people to join us to create a great cause! | $15.8M | Series A | Mar 09, 2022 |  |
| Geneus | Geneus is a developer of gene sequencers and reagents. |  | Series B | Sep 28, 2021 |  |
| Sanyou Bio | Sanyou Biopharmaceuticals Co., Ltd. is a leading international CRO (contract research organization) company focused on R&D and services to create innovative antibody drugs. The company has established an integrated innovative antibody drug R&D laboratory of several thousand square meters with advanced facilities in Caohejing Hi-Tech Park.During the last five years, Sanyou built and validated more than 20 core technological platforms such as: innovative antibody drug discovery, antibody engineering, in vivo and in vitro drug efficacy evaluation, stable cell line construction, and production process development. |  | Series B | Jun 25, 2021 |  |
| HiFiBiO Therapeutics | HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rootedbiological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France. | $75M | Series D | Jun 14, 2021 |  |
| Neurophth Therapeutics | Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally. | $61.9M | Series B | Feb 09, 2021 |  |

8 of 8 investments shown.

## Co-investors
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 4 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 4 deals together
- [Alibaba Group](https://shizune.co/investors/profile/alibaba) — VC Fund, 1 deal together
- [WeDo Capital Management](https://shizune.co/investors/profile/beijing-weidu-capital-management) — VC Fund, 1 deal together
- [Blue Focus PR Consulting](https://shizune.co/investors/profile/blue-focus-pr-consulting) — VC Fund, 1 deal together
- [China Capital Management](https://shizune.co/investors/profile/china-capital-management) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Medical Device VC Funds in China](https://shizune.co/investors/medical-device-vc-funds-china)

## FAQ

### What does Grand Mount Capital invest in?

Grand Mount Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Grand Mount Capital last invest?

The most recent investment recorded for Grand Mount Capital closed in Jul 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co